{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T13:14:24Z","timestamp":1656249264830},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Pharmacy and Nutrition"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Using a standardized approach to describe the sources of uncertainty in cost-effectiveness analyses might bring added value to the local critical assessment procedure of reimbursement submissions in Hungary. The aim of this research is to present a procedural framework to identify, quantify and interpret sources of uncertainty, using the reimbursement dossier of darolutamide as an illustrative example.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the procedural framework designed for the critical assessment of cost-effectiveness analyses, the quantifiability of an identified source of uncertainty is assessed through the input parameters of the originally submitted model, which is followed by the interpretation of its impact on estimates of costs and outcomes compared to the base case cost-effectiveness conclusion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Based on our experiences with the recent reimbursement dossier of darolutamide, the significant and quantifiable sources of uncertainty were the time horizon of the economic analysis; the restriction of the efficacy analysis population; long-term relative effectiveness of darolutamide; price discount on subsequent therapies. We identified resource use patterns for comparator and subsequent therapies as a quantifiable, yet non-significant source of uncertainty. The EQ-5D value set used to estimate utility values was identified as a non-quantifiable and potentially not significant source of uncertainty.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The procedural framework, demonstrated with an example, was sufficiently flexible and coherent to document and structure the sources of uncertainty in cost-effectiveness analyses. The full-scale use of this framework is desirable during the decision-making process for reimbursement in Hungary. The further formalization of identifying sources of uncertainty is a possible subject of methodological development.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-022-08214-9","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T08:03:09Z","timestamp":1656144189000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A critical assessment framework to identify, quantify and interpret the sources of uncertainty in cost-effectiveness analyses"],"prefix":"10.1186","volume":"22","author":[{"given":"Gerg\u0151","family":"Mer\u00e9sz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"D\u00f3czy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ron","family":"H\u00f6lgyesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gergely","family":"N\u00e9meth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,25]]},"reference":[{"key":"8214_CR1","unstructured":"On the Criteria of the Inclusion of Registered Medicines and Special Nutritional Formulae into Social Health Insurance Financing and on the Modification of the Inclusion Decision or the Extent of the Subsidy. Budapest: ESzCsM of the Minister of Health, Social and Family Affairs; 2004. Available from: https:\/\/njt.hu\/jogszabaly\/2004-32-20-0M"},{"key":"8214_CR2","unstructured":"Methodological guidelines for conducting and assessing economic analyses in healthcare [Internet]. Budapest: Ministry of Human Resources; 2021 p. 2178. Available from: http:\/\/www.kozlonyok.hu\/kozlonyok\/Kozlonyok\/6\/PDF\/2021\/21.pdf"},{"issue":"6","key":"8214_CR3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","volume":"15","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Heal. 2012;15(6):835\u201342.","journal-title":"Value Heal"},{"key":"8214_CR4","doi-asserted-by":"crossref","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Health Serv Res. 2022;22(1):3\u20139. Available from:\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/35081957\/. Cited 9 Apr 2022.","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"8214_CR5","unstructured":"Critical Appraisal Skills Programme. Home - CASP - Critical Appraisal Skills Programme. 2020. Available from: https:\/\/casp-uk.net\/. Cited 5 Jun 2020."},{"key":"8214_CR6","doi-asserted-by":"crossref","unstructured":"Inotai A, P\u00e9kli M, J\u00f3na G, Nagy O, Rem\u00e1k E, Kal\u00f3 Z. Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: Publication of the critical appraisal methodology. BMC Health Serv Res. 2012;12(1):332. Available from:\u00a0https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/1472-6963-12-332. Cited 11 Aug 2020.","DOI":"10.1186\/1472-6963-12-332"},{"key":"8214_CR7","unstructured":"EUnetHTA. Practical considerations when critically assessing economic evaluations. 2020. Available from: https:\/\/eunethta.eu\/wp-content\/uploads\/2020\/03\/EUnetHTA-JA3WP6B2-5-Guidance-Critical-Assessment-EE_v1-0.pdf. Cited 5 Jun 2020."},{"key":"8214_CR8","unstructured":"A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer. NCT02200614. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02200614. Cited 13 Jun 2021."},{"key":"8214_CR9","unstructured":"Shkolnikov V, Barbieri M, Wilmoth J. The Human Mortality Database. 2021. Available from: https:\/\/www.mortality.org\/. Cited 13 Jun 2020."},{"key":"8214_CR10","doi-asserted-by":"crossref","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med. 2020;383(11):1040\u20139.\u00a0Available from:\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/32905676\/. Cited 13 Jun 2021.","DOI":"10.1056\/NEJMoa2001342"},{"key":"8214_CR11","unstructured":"Administration NHIF. Risk Sharing Agreements. 2021. Available from: http:\/\/www.neak.gov.hu\/felso_menu\/szakmai_oldalak\/gyogyszer_segedeszkoz_gyogyfurdo_tamogatas\/egeszsegugyi_vallalkozasoknak\/gyartok_forgalomba_hozok\/tam_vol.html. Cited 13 Jun 2020."},{"key":"8214_CR12","unstructured":"Administration NHIF. Purchase order for enzalutamide. FO82\/8-94\/2017. 2017. p. 26. Available from: https:\/\/kereso-core.kozbeszerzes.hu\/data\/dokumentumtar\/2876\/93553754-cad5-41d7-8cdb-abd55cd0b2ff.pdf"},{"key":"8214_CR13","unstructured":"Administration NHIF. Purchase order for abirateron. FO82\/10-192\/2017. 2017. p. 20. Available from:\u00a0https:\/\/kereso-core.kozbeszerzes.hu\/data\/dokumentumtar\/2935\/7831654b-70e9-4e4a-a489-6187314b04ed.pdf."},{"key":"8214_CR14","doi-asserted-by":"crossref","unstructured":"Rencz F, Brodszky V, Gul\u00e1csi L, Golicki D, Ruzsa G, Pickard AS, et al. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. Value Heal. 2020;23(9):1235\u201345.\u00a0Available from:\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/32940242\/. Cited 13 Jun 2020.","DOI":"10.1016\/j.jval.2020.03.019"},{"issue":"6","key":"8214_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jval.2016.08.729","volume":"20","author":"C Carroll","year":"2017","unstructured":"Carroll C, Kaltenthaler E, Hill-McManus D, Scope A, Holmes M, Rice S, et al. The Type and Impact of Evidence Review Group Exploratory Analyses in the NICE Single Technology Appraisal Process. Value Heal. 2017;20(6):785\u201391.","journal-title":"Value Heal"},{"key":"8214_CR16","doi-asserted-by":"crossref","unstructured":"Fenwick E, Steuten L, Knies S, Ghabri S, Basu A, Murray JF, et al. Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value Health. 2020;23(2):139\u201350. Available from:\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/32113617\/.\u00a0Cited 11 Apr 2022.","DOI":"10.1016\/j.jval.2020.01.001"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08214-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-022-08214-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08214-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T08:04:46Z","timestamp":1656144286000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-022-08214-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["8214"],"URL":"https:\/\/doi.org\/10.1186\/s12913-022-08214-9","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,25]]},"assertion":[{"value":"13 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"822"}}